Absolute Benefit for Adjuvant Chemotherapy in Early Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO

  • Data from the Early Breast Cancer Trialists’ Collaborative Group:
    • Meta-analysis of adjuvant systemic therapy trials begun in or before 1995:
      • Show a 30% relative reduction:
        • In breast cancer-related mortality:
          • Associated with adjuvant hormonal therapy and with adjuvant chemotherapy
    • Reduced ratesof:
      • Ipsilateral local recurrence, contralateral cancers, and distant metastases in treated patients:
        • Suggest there is eradication of occult residual disease in many patients
    • The absolute survival benefit of adjuvant therapy:
      • Is greater in node-positive than in node-negative patients
    • The absolute survival benefit of chemotherapy:
      • Is greater for younger (less than 50 years of age) than for older women (50 to 69 years of age)
  • References:
    • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
    • Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.

#Arrangoiz #BreastCancer #CancerSurgeon #SurgicalOncologist #Cancer #BreastSurgeon #BreastExpert

Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment